PAX Financial Group LLC Purchases New Stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

PAX Financial Group LLC acquired a new position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 12,832 shares of the company’s stock, valued at approximately $27,000.

Several other hedge funds have also recently bought and sold shares of ALLO. Zacks Investment Management acquired a new stake in shares of Allogene Therapeutics during the 3rd quarter worth approximately $1,446,000. Geode Capital Management LLC boosted its stake in shares of Allogene Therapeutics by 14.4% in the 3rd quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock valued at $9,037,000 after purchasing an additional 407,070 shares in the last quarter. abrdn plc acquired a new stake in shares of Allogene Therapeutics in the 4th quarter valued at approximately $776,000. Vontobel Holding Ltd. grew its holdings in shares of Allogene Therapeutics by 788.4% during the 4th quarter. Vontobel Holding Ltd. now owns 195,457 shares of the company’s stock valued at $416,000 after purchasing an additional 173,457 shares during the last quarter. Finally, Barclays PLC increased its position in Allogene Therapeutics by 101.5% during the 3rd quarter. Barclays PLC now owns 342,973 shares of the company’s stock worth $959,000 after purchasing an additional 172,745 shares in the last quarter. 83.63% of the stock is owned by institutional investors.

Allogene Therapeutics Trading Up 4.3 %

ALLO stock opened at $1.44 on Friday. The firm has a market cap of $312.86 million, a PE ratio of -0.92 and a beta of 0.99. The stock has a 50-day moving average price of $1.81 and a 200-day moving average price of $2.20. Allogene Therapeutics, Inc. has a 1-year low of $1.30 and a 1-year high of $4.25.

Allogene Therapeutics (NASDAQ:ALLO) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.06. On average, analysts forecast that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current year.

Insider Buying and Selling

In other Allogene Therapeutics news, EVP Zachary Roberts sold 27,199 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total value of $48,414.22. Following the completion of the sale, the executive vice president now owns 488,054 shares of the company’s stock, valued at approximately $868,736.12. This trade represents a 5.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Timothy L. Moore sold 14,746 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $1.71, for a total value of $25,215.66. Following the completion of the transaction, the insider now owns 250,713 shares in the company, valued at approximately $428,719.23. This represents a 5.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 104,866 shares of company stock valued at $194,461 over the last ninety days. 24.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. HC Wainwright decreased their target price on shares of Allogene Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, March 19th. Citizens Jmp raised Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 target price for the company in a report on Friday, March 14th. Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 target price on shares of Allogene Therapeutics in a research report on Friday, March 14th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $10.00 price target on shares of Allogene Therapeutics in a report on Friday, March 14th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $9.29.

Allogene Therapeutics Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).